L1CAM immunoaffinity‐capture has been used to separate ‘CNS‐EVs’ from AD patient plasma, which showed a significant increase in Aβ1−42 up to 10 years before the onset of AD (Fiandaca et al., 2015). Here, L1CAM is linked to Alzheimer disease.